Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
14 June 2019 | Story Valentino Ndaba | Photo Albert van Biljon
Alison Botha
Over and above being a survivor, Alison Botha is an inspiration.

It was an ordinary December 1994 evening in Port Elizabeth. Alison Botha parked her car in front of her home. A man ambushed her at knife point. Minutes later, she was forced into the passenger seat and the perpetrator drove off, picking his friend up on their way to the coastal bushes of the city.
 
What was supposed to be an ordinary evening turned into a horrific experience which changed Botha’s life forever. She was raped, strangled, had her throat slit and her stomach cut open. Physicians called her survival a medical miracle. The true miracle though, is how she has chosen to deal with the experience. 

Botha overcame her fear of public speaking and has become an international motivational speaker who also authored a first-person account of her ordeal and recovery in 1998, titled I Have Life.

Aluta continua against gender-based violence

As part of our university’s advocacy against gender-based violence, the Human Resources’ Division for Organisational Development and Employee Wellness hosted Botha for a motivational talk on 5 June 2019 at the Bloemfontein Campus. In telling her story, Botha stated that she still receives healing.

While welcoming guests and the speaker, Prof Prakash Naidoo, Vice-Rector: Operations touched on Project Caring which is supported by the Rectorate. “We care for you and part of that caring agenda is gender-based violence. We encourage you to speak out about this issue, don’t remain silent, someone will listen,” he advised.

From victim to victor

Botha believes that if her story serves to help someone else avoid the same situation or perhaps even survive a similar trauma, then she has served her purpose. “I now believe that the evil is far outweighed by all the good that has come out of my choice to share my story,” she said.

Much of the reason behind her strength lies in what she terms her own ABC principle which speaks to attitude, belief and choice. “We are not always going to be in control of everything that happens to us. But we always control how we respond,” said Botha. 

The story of Botha’s survival, recovery and victory proves that the human spirit cannot be crushed. There is indeed life after a near-death tragedy.

News Archive

Researchers receive study grant for research into Congo Fever
2015-03-10

UFS researchers will be contributing significantly to the search for a vaccine against the deadly tick-borne disease known as Congo Fever.

Prof Felicity Burt from the Department of Medical Microbiology and Virology was recently awarded a research grant by the National Health Laboratory Service (NHLS) to study candidate vaccines for Crimean-Congo heamorrhagic fever (CCHF) virus and other arboviruses.

Arboviruses are viruses transmitted by mosquitoes, ticks, or other arthropods.

Prof Burt is an internationally-recognised expert on the Crimean-Congo haemorrhagic fever (CCHF). The Crimean-Congo haemorrhagic fever (CCHF) virus is a tick-borne virus that is associated with severe haemorrhagic disease in South Africa and other parts of Africa, Asia, and eastern Europe. Her interests focus on medically significant viruses that are transmitted by ticks and mosquitoes. Her research group is involved in determining the immune responses that are induced by different viral proteins.

Crimean-Congo haemorrhagic fever (CCHF) virus, a tick- borne virus found in Africa, Asia, the Balkans, and eastern Europe, causes severe viral haemorrhagic fever outbreaks.

Although a number of tick species are capable of becoming infected with CCHF virus, ticks of the genus Hyalomma, commonly referred to in SA as the “bont-legged ticks”, are the principal vector. The ticks have distinctive brown and white bands on their legs.

In February 1981, the first case of CCHF was recognised in South Africa (SA). To date, there have been nearly 200 cases of CCHF infection in SA with a 20% fatality rate. The majority of cases occurring in SA were in patients from the Northern Cape and Free State provinces.

“The funding that has been awarded will be used to profile immune responses against CCHF viral proteins, and investigate mechanisms and strategies to enhance these immune responses. We hope that the study will contribute knowledge towards the development of a vaccine against this medically significant virus.”

For more information or enquiries contact news@ufs.ac.za.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept